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MinireviewCholesterol and the Biology
of Alzheimer’s Disease
tors for apo E in the brain. Upon uptake, the apolipopro-
teins are shuttled through the endosome, and the cho-
lesterol is transported to the endoplasmic reticulum via
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a vesicle that contains the protein NPC1, which is inacti-Building 102, Room 3634
vated in Neimann-Picks disease (Figure 1, steps 3 and 4).2160 South 1st Avenue
As cholesterol is inserted into the membrane, it becomesMaywood, Illinois 60153
concentrated in small patches on the plasma mem-
brane, termed lipid rafts, where it facilitates packing of
the sphingomyelin. Many transmembrane receptors and
enzymes function best in the cholesterol-rich environ-Recent results implicating cholesterol metabolism in
ment of lipid rafts.the pathophysiology of Alzheimer’s disease (AD) bring
Cholesterol and the Processing of Amyloidcholesterol to the forefront of AD research. Research
Precursor Proteinfrom genetics, epidemiology, and cell biology all con-
Production of -amyloid appears to play a central roleverge, suggesting that cholesterol plays a central role
in the pathophysiology of AD. Cholesterol impacts onin the biology of amyloid precursor protein and the
production of A because amyloid precursor proteintoxic peptide generated by its cleavage, -amyloid
(APP) and the enzymes that cleave APP to generate(A). The ability of cholesterol to modulate A produc-
-amyloid are transmembrane proteins (Figure 1, step 7).tion suggests opportunities for therapeutic interven-
APP is a protein that contains a single transmembranetion, although the functional significance underlying
domain. As APP matures it is glycosylated and then mostthe connection between cholesterol and A remains
of the protein is cleaved first by- or-secretase, followedto be investigated.
by -secretase. The -secretase pathway is critical to
the amyloid hypothesis because it generates A. APPCholesterol Metabolism
flowing through the -secretase pathway is first cleavedAny discussion of how cholesterol impacts on AD must
by -secretase (BACE, also known as memapsin 2) andbegin with a review of the major elements of cholesterol
then cleaved by the -secretase complex, which yieldsmetabolism because a surprising number of these pro-
A (Figure 1, step 7). Several proteins are capable ofteins affect the production of A. Cholesterol is the prod-
producing the -cleavage; these proteins include theuct of a multienzyme cascade that begins with the ac-
ADAM family of metalloproteases as well as other prote-tions of -hydroxy--methylglutaryl CoA (HMG CoA)
ases, such as BACE2.synthase and HMG CoA reductase. The latter enzyme
A critical reason that A production is sensitive tois the target of statins, which are one of the most suc-
cholesterol levels is because the activity of - andcessful classes of medicines on the market today. Cho-
-secretase complexes are very dependent on choles-lesterol homeostasis is maintained by the interplay
terol metabolism. Both - and -secretase complexesbetween synthesis, uptake, and catabolism. Excess
reside in cholesterol-rich lipid domains within the mem-cholesterol is eliminated by acetylation or oxidation.
brane. BACE appears to be particularly sensitive toCholesterol destined for storage is acetylated by acyl-
membrane cholesterol content and is located in lipidcoenzyme A cholesterol acyltransferase (ACAT; Figure
rafts; reducing cellular cholesterol appears to inhibit1, step 5a; Puglielli et al., 2001). Cholesterol destined
BACE activity (Cordy et al., 2003; Fassbender et al.,for elimination as bile acid is oxidized by 7 cholesterol
2001). -secretase also resides in lipid rafts and the
hydroxylase (Cyp7a). Cholesterol can also be oxidized
-cleavage has also been shown to be affected by cho-
at the 24 or 27 positions by the mitochondrial enzymes,
lesterol content (Wahrle et al., 2002). In contrast, the
cholesterol 24 hydroxylase (Cyp46) and cholesterol 27 enzymes of the -secretase pathway reside in the phos-
hydroxylase (Cyp27), to generate oxysterols; oxidation pholipid-rich domain of the plasma membrane and show
at the 25 position also occurs to a lesser extent (Figure increased activity when cellular cholesterol content is
1, step 5b; Russell, 2003). Both bile acids and oxysterols lowered (Figure 1, step 8; Kojro et al., 2001). Thus, reduc-
are ligands for transcription factors. Oxysterols bind to ing neuronal cholesterol (by treating neurons with statins
the nuclear receptors liver X receptor (LXR) and farnesyl or -methylcyclodextran) decreases the amount of A
X receptor (FXR), which dimerize with the retinoic acid secreted by the neurons, probably because of reduced
receptor, and stimulate transcription of proteins impor- -secretase activity, and increases the amount of APPs
tant to cholesterol metabolism and to Alzheimer’s disease, secreted by the neurons.
such as apolipoprotein E and the ABCA1 transporter (Fig- Neurons in the brain respond to changes in choles-
ure 1). The enzymes that transport cholesterol, such as terol much like neurons in cell culture. Guinea pigs or
apolipoproteins E (apo E), are also relevant to AD. Apo E mice treated with statins have lower A levels in their
is the main transport protein in the brain, and although cerebrospinal fluid (Fassbender et al., 2001; Petanceska
there are many lipoprotein receptors, the low-density et al., 2002). Statin treatment reduces the accumulation
lipoprotein receptor related protein (LRP) and the very of A and neuritic plaques in transgenic tg2576 mice
low-density lipoprotein receptor are the principle recep- that overexpress APP (Refolo et al., 2001). Statins also
lower A in humans (Friedhoff et al., 2001). Inhibiting
cholesterol metabolism through other mechanisms also*Correspondence: bwolozi@lumc.edu
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logical alterations in cholesterol levels alter A produc-
tion in vivo.
Cholesterol Genes and the Genetics
of Alzheimer’s Disease
Molecular genetics provides further evidence implicat-
ing abnormalities in cholesterol biology with AD. Genetic
linkage for AD has been established for four genes: APP,
presenilin 1, presenilin 2, and apo 4. The linkage to
APP and the presenilins relate to early-onset AD, while
apo 4 shows linkage in AD families with a later onset.
Recent years have brought a flurry of putative associa-
tion between AD and other genes, but the strength of
the associations remains to be established. Some of
these putative associations include genes that are in-
volved in cholesterol metabolism, which is particularly
relevant to the putative role of cholesterol in AD. The
association of increased cholesterol synthesis or flux
with increased A secretion suggests a hypothesis that
polymorphisms in cholesterol metabolism increase the
risk of AD by increasing secretion of A. The apo 4
polymorphism is the single greatest risk factor for AD.
Approximately 40% of AD subjects have at least one apoFigure 1. The Flux of Cholesterol through the Cell
4 allele, and being homozygous for apo 4 increasesNeurons take up HDL-like particles generated by astrocytes that
the risk of AD 4-fold. The leading hypotheses for thecontain apo E, which readily binds A. (1) The HDL-apo E-A com-
plex binds to lipid receptors, such as LRP. (2) This complex is taken mechanism by which apo E4 increases the risk of AD
up by endocytosis of cholesterol- and caveolin-rich membranes to is that apo E4 binds A and promotes the aggregation of
form endosomes. (3) Cholesterol in the endosome is shuttled to a A or reduces clearance of aggregated A. Transgenic
vesicle that contains the NPC1 cholesterol transport protein, while mice that overexpress APP but lack apo E exhibit re-
some proteins are shuttled toward the lysosome for degradation.
duced A accumulation after 1 year, although the amy-(4) The NPC1 protein transports the cholesterol to the endoplasmic
loid accumulation is greater after 2 years. Knockin ofreticulum. (5a) Excess cholesterol in the endoplasmic reticulum can
human apo E4 leads to increased A deposition. Thebe stored by conversion to cholesterol ester. (5b) Alternatively, ex-
cess cholesterol can be secreted by conversion to oxysterols; the cumulative mouse data provide clear evidence that apo
main enzymes that oxidize cholesterol, Cyp46 and Cyp27, are lo- E plays an important role in modulating A accumulation
cated in the mitochondria. (6) Cholesterol continues to be added in the brain by stimulating A aggregation but also by
to the membrane as movement occurs through the endoplasmic
promoting A clearance. However, the apo E4 isozymereticulum to the trans-golgi network. A also begins to be generated
also increases the risk of a number of disorders that doin the endoplasmic reticulum and continues to be generated in the
not exhibit A aggregation. For instance, the presencetransgolgi network. (7) The presence of cholesterol-rich lipid rafts
increases A production. (8) Phospholipid-rich, cholesterol-poor of the apo E4 isozyme modulates the age of onset or
membranes favor production of APPs. (9) Oxysterols act in concert risk of Pick’s disease, Parkinson’s disease, dementia
with retinoic acid to stimulate transcription of the cholesterol trans- pugilistica, and cognitive deficits following stroke.
porter ABCA1 (a), and ABCA1 stimulates efflux of cholesterol and These data suggest pleiotropic actions for apo E and
oxysterols from the cell (b).
raise the possibility that the apo E4 might exert other
deleterious affects on the brain. In this context, the func-
tion of apo E as a cholesterol transport protein could
reduces A production. Reducing cholesterol esters by be an intriguing connection. A full understanding of how
inhibiting ACAT (Figure 1, step 5a) inhibits secretion of apo E4 affects the pathophysiology of these diseases
A (Puglielli et al., 2001). Blocking cholesterol trafficking, remains to be elucidated.
by mutation of NPC1 (Figure 1, step 4) or treatment The putative relationship between cholesterol biology
with A1866 (Figure 1, step 4), also inhibits A secretion, and AD is particularly interesting because increasing
although A accumulates intracellularly when NPC1 is numbers of studies suggest an association between
mutated (Burns et al., 2003; Refolo et al., 2001). Reduc- other genes implicated in cholesterol biology and AD.
ing cholesterol content by transfecting with the ABCA1 Two different polymorphisms in Cyp46 (also known as
cholesterol transporter and increasing cholesterol efflux cholesterol 24 hydroxylase) have been associated with
(Figure 1, step 9) also reduces A secretion (Sun et al., AD in two studies, although a third study failed to ob-
2003). Oxysterols, which increase synthesis of many serve the association (Desai et al., 2002; Kolsch et al.,
proteins including ABCA1, also reduce A production 2002). Polymorphisms in ABCA1, which is a cellular cho-
(Koldamova et al., 2003; Sun et al., 2003). Increasing lesterol transporter, are also associated with AD (Woll-
cholesterol appears to have the opposite effect, be- mer et al., 2003). As with the Cyp46 polymorphisms,
cause feeding transgenic APP mice high cholesterol these polymorphisms are associated with increased lev-
diets increases amyloid burden (Refolo et al., 2000). els of A in the CSF. Although no polymorphisms in LRP
These data demonstrate a close connection between have yet to be positively associated with AD, polymor-
cellular cholesterol content and A secretion. However, phisms in LRP and LRP-associated protein might be
because most of these experiments utilize highly per- negatively associated with AD (Kolsch et al., 2003; San-
chez et al., 2001). Subjects with AD are less likely toturbed systems, it remains to be seen whether physio-
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have a particular insertion in the gene and exhibit an that subtle bias in patient selection, such as the use of
odds ratio of 0.18 for this insertion with respect to the subjects with high cholesterol, might have altered the
risk of AD. As more single nucleotide polymorphisms PROSPER study, or that the study was not properly
are studied, it seems likely that an increasing number designed to detect dementia (Shepherd et al., 2002).
of genes related to cholesterol metabolism will be asso- For instance, the psychometric indices in the PROSPER
ciated with AD. However, many of the associations be- study were determined by phone interview, which is a
tween cholesterol-related genes and AD remain weak. very crude mechanism for performing such studies. The
The evolution of our understanding of the importance abnormally low rate of dementia seen among subjects
of cholesterol in AD will strongly depend on whether in the PROSPER study (less than 10% of the expected
further studies strengthen these associations. rate) might reflect the weakness of the cognitive testing.
Statin Therapy for Alzheimer’s Disease? The negative outcome of the PROSPER study suggests
The responsiveness of A production to cholesterol lev- that current and future studies prospectively examining
els suggests that reducing cholesterol might lower the the efficacy of statins in preventing AD need to carefully
risk of AD. Several studies indicate that subjects with examine the criteria for subject selection and method
elevated mid-life cholesterol are at increased risk for of cognitive evaluation.
AD, and elevated cholesterol is associated with higher Conclusion
plaque load in AD subjects (Kivipelto et al., 2002). Statins The research on the putative role of cholesterol in AD
are widely used in the population and reduce serum identifies an important regulatory axis for APP pro-
cholesterol very effectively. Treating subjects with cessing and A production that is only beginning to be
doses of statins used in clinical management of hyper- explored. The simplest explanation for sensitivity of APP
cholesterolemia reduces A in human plasma and in processing to cholesterol is chemical; the transmem-
human cerebrospinal fluid by almost 40% (Friedhoff et brane proteins that process APP might simply require
al., 2001). Interestingly, hydrophobic statins and hydro- a high cholesterol environment to function. A somewhat
philic statins appear to reduce the levels of 24 hydroxy- more biological hypothesis is that regulation of APP
cholesterol equally (Vega et al., 2003). This is surprising processing is designed to respond to changes in choles-
because the blood-brain barrier permeability of statins terol membrane dynamics. For instance, synaptic plas-
differs greatly depending on lipophilicity. This suggests ticity requires changes in cholesterol, lipids, and mem-
that the statins could be acting at the level of the cerebral brane proteins, possibly including those controlling APP
endothelium. Whether statins reduce cerebral A by processing. The association of APP and A with uptake
lowering cholesterol in the brain or by another mecha- of cholesterol (via LRP and apo E) also raises the possi-
nism remains an open question. Statins have been shown bility that APP or A contributes to cholesterol traffick-
to inhibit endothelin-1 expression and to prevent oxi- ing. However, although cholesterol clearly influences
dized LDL from inhibiting the expression of endothelial APP metabolism, data has yet to surface suggesting
nitric oxide synthase (Hernandez-Perera et al., 1998). that APP influences cholesterol metabolism.
Eckert and colleagues observed that statins do not mod- The ability of cholesterol to modulate A production
ulate brain cholesterol in apo E knockout mice, which combined with the utility of statins in health care sug-
suggests that statins regulate brain cholesterol through gests that this is a fertile avenue of research for treating
a mechanism that requires apo E (Eckert et al., 2001). AD. However, even if statins are not found to be benefi-
The presence of astrocytic end-feet on cerebral endo- cial for those AD patients, cholesterol metabolism pre-
thelial cells raises the possibility that statins are sensed sents multiple targets for inhibiting A production. Inhib-
by astrocytes, which then reduce the secretion of cho- itors for ACAT exist and show promise for lowering A,
lesterol and apo E. Finally, statins might directly interact and NPC1, cholesterol hydroxylases, cholesterol trans-
with other, as yet undefined, enzymes that influence porters, and lipoprotein receptors are all potential tar-
A production.
gets for drug development. Since cholesterol metabo-
The efficacy of statins toward AD is beginning to be
lism is also inherently important for synaptic plasticity,
examined in clinical studies. Epidemiological studies
increased understanding of cerebral cholesterol metab-indicate that there is up to a 70% lower prevalence and
olism could also lead to important advances in otherincidence of AD in subjects taking statins (Jick et al.,
fields, such as synaptic plasticity, development, and2000; Wolozin et al., 2000). This is true even after correct-
neuroregeneration.ing for confounding issues such as physician or patient
bias. The prospective data on statin therapy for AD,
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